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I-27 TARGETING NF-KAPPAB SIGNALING IN OA: IS IT ONLY
ABOUT INFLAMMATION?
K.B. Marcu1,2, E. Olivotto3, S. Pagani3, A. Facchini3, R. Borzi3. 1Stony
Brook University, Stony Brook, NY, USA, 2University of Bologna,
Bologna, ITALY, 3Rizzoli Institute, Bologna, ITALY
Purpose: To provide evidence in support of the hypothesis that selectively
impeding OA chondrocyte differentiation towards a hypertrophic-like state
(by blocking NF-kappaB independent functions of IKKalpha) could repre-
sent a rational strategy for ameliorating the course of OA disease. Without
argument OA is a complex often considered untreatable disease that
develops with ageing due to a variety of genetic and environmental phe-
nomena. Abnormal, progressive changes occur in the delicate balance
between anabolic and catabolic processes of chondrocyte homeostasis
in OA, thereby tipping the balance in favor of deregulated catabolic
activity, excessive ECM remodeling and thus cartilage degradation. This
excessive degree of cartilage destruction has a strong inﬂammatory
component, as is the case for other debilitating, ageing associated
diseases; but it remains unclear whether an inﬂammatory state actually
initiates or exacerbates OA phenotype. Importantly OA pathology is also
characterized by cycles of attempts at faulty ECM repair and enhanced
angiogenesis in conjunction with chondrocyte hypertrophy leading to
abnormal endochondral ossiﬁcation that produces underlying bone thick-
ening and the appearance of bony outgrowths. The latter features of OA
disease are suggestive of speciﬁc perturbations in cellular homeostasis
characterized by faulty, inappropriate chondrocyte differentiation. Along
this line of reasoning selectively impeding adult articular chondrocyte
differentiation towards a hypertrophic-like condition in OA could represent
a logical strategy for stabilizing chondrocyte ECM and maintaining their
normal homeostasis in general to avoid the onset of disease phenotype.
In this regard experimental evidence will be presented that IKKalpha
plays a surprisingly NF-kappaB independent, important role in modulating
the onset of ECM remodeling in conjunction with the conversion of
chondrocytes to a hypertrophic-like status and as such could represent
a novel OA target.
Methods: Stable retroviral transduction of targeted interfering RNAs
into OA and normal chondrocytes, in vitro chondrocyte differentiation,
immunohistochemistry, immunoblotting, Elisa, real time PCR.
Results: Ablation of either IKKbeta or IKKalpha expression blocked ECM
remodeling and chondrocyte differentiation by NF-kappaB dependent
and independent mechanisms respectively. Importantly IKKalpha knock-
down (KD) profoundly blocked chondrocyte differentiation prior to the
onset of ECM remodeling. Moreover IKKalpha compromised articular
chondrocytes maintained a highly organized ECM in conjunction with
enhanced cell viability. IKKalpha KD suppressed MMP13 activity but not
its expression. Interestingly we also ﬁnd that IKKalpha KD and MMP13
KD chondrocytes share a number of common features.
Conclusions: The NF-kappaB signaling pathway and a signiﬁcant por-
tion of its downstream target genes are well known to orchestrate cellular
stress-like responses. Moreover NF-kappaB deregulation strongly con-
tributes to the poor prognosis of diseases with a strong inﬂammatory
component, thus also making it a preferred OA target. However anti-NF-
kappaB based therapeutics can be a double edged sword due to poten-
tially deleterious consequences for cell survival and other targeted anti-
inﬂammatory modalities (including anti-MMP or anti-Cox or anti-Il-1beta
based therapeutics) can cause unwanted, collateral side affects. Our new
ﬁndings provide evidence that IKKalpha, in a kinase and NF-kappaB
independent pathway, could represent a novel OA disease target. Future
experiments will in part be devoted to establishing a functional role for
IKKalpha in an in vivo OA model, wherein IKKalpha ablation is induced in
murine chondrocytes in vivo during the course of experimentally induced
OA disease.
I-28 INFLAMMATION IN OA AS A TREATMENT TARGET
F. Iannone Sr, G. Lapadula Sr.. DiMIMP – Rheumatology Unit, Bari,
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Purpose: Osteoarthritis (OA) is a multifactorial disease in which joint
failure results from an intricate interplay among the pathologic processes
taking place in cartilage, synovial membrane (SM) and subchondral bone.
The speciﬁc contribute of each of these tissues in determining the joint
damage is matter of debate. SM is generally believed to play a minor role
in OA pathogenesis and to be involved following the release of cartilage
debris that would induce the SM reaction and inﬂammation. Inﬂamed
SM secrete an array of proinﬂammatory molecules which implement the
cartilage damage by promoting the activation of MMP (metalloproteinase)
cascade leading to matrix breakdown.
We focused on the possible early involvement of the SM in OA patho-
physiology and on the role of some inﬂammatory mediators in causing
cartilage damage.
Methods: We induced right knee OA in nine goats by resecting the ante-
rior cruciate ligament (ACL). Histology of SM, cartilage and subchondral
bone was performed and the expression of Il-1 and Il-4 was assessed by
immunohistochemistry and ﬂowcytometry. Our experimental model has
shown that cartilage and SM were ﬁrstly and simultaneously involved
in OA (at 1 month) whilst morphometric analysis of subchondral bone
detected signiﬁcant differences between OA and control knee only after
6 months. Furthermore, the expression of Il-1 was already increased
in SM at 1 month and, interestingly, the intracellular levels of Il-4 were
signiﬁcantly increased in OA cultured osteoblasts not before 3 months.
Results: Among the proinﬂammatory mediators produced by the SM,
substance P (SP) is an intriguing molecule with pleiotropic functions. SP
is a neuropeptide released from the ﬁbers C terminal nerve endings
and plays a pivotal role in controlling nociception, vascular tone and
inﬂammation. SP has been found increased in synovitis and is also
directly produced by synoviocytes. We demonstrated that chondrocytes
synthesize SP and its expression increased in human OA chondrocytes
both at mRNA (RT-PCR) and protein (ﬂocytometry) levels. Furthermore,
the cell-membrane bound peptidases (CD10 and CD26), which hydrolyze
the neuropeptides, were found decreased on OA human chondrocyte
surface. To further explore the role of SP in cartilage metabolism and OA
pathogenesis, we studied its effect on proteoglycans (PG) remodeling and
aggrecanase-5 (ADAMTS-5) and MMP-13 synthesis. Preliminary data
suggest the SP (10−8 M) increases the breakdown of PG from both OA
and normal cartilage explants, as indicated by reduced safranin staining,
and enhances the release of ADAMTS-5 and MMP-13 (western blot).
Preincubation with spantide II (a selective antagonist of SP) prevents
these effects. Nevertheless, TIMP-3, a speciﬁc inhibitor of ADAMTS-5,
does not seem to be regulated by SP. Hence, SP, beside its proinﬂam-
matory functions, exerts a direct effect on matrix cartilage remodeling
and its increase in OA may represent a further mechanism of cartilage
damage.
Conclusions: The relevance of inﬂammation in OA pathophysiology is
worthy of further studies since its role in OA is not limited to appearance
of pain but directly takes part to joint damage and its targeting, since
the early stage of disease, with selective modulators can be a promising
strategy to cure OA.
I-29 DISCOVERY AND VALIDATION OF AN IMMUNOAFFINITY
LC-MS/MS ASSAY FOR THE QUANTIFICATION OF THE
COLLAGEN TYPE II NEOEPITOPE PEPTIDE BIOMARKER
O. Nemirovskiy1, W. Li2, S. Fountain2, T. Sunyer1, W. Mathews1,
G. Szekely-Klepser3, M-P. Hellio Le Graverand4. 1Pﬁzer, Inc., St. Louis,
MO, USA, 2Pﬁzer, Inc., La Jolla, CA, USA, 3Assay Designs, Ann Arbor,
MI, USA, 4Pﬁzer, Inc., Groton, CT, USA
Purpose: To validate an assay for the quantiﬁcation of type II collagen
neoepitope (TIINE) peptides for its biomarker applications. Application of
a biomarker in scientiﬁc decision making requires its validation for the
given purpose and therefore, should include two distinct activities: tech-
nical validation of the assay procedure and biological/pharmacological
validation for its ﬁt-for-purpose use. This work describes recent discovery
and analytical validation of the immunoafﬁnity LC-MS/MS assay for the
quantiﬁcation of the TIINE 45-mer peptide in human urine to demonstrate
that the assay is speciﬁc, sensitive and reliable (precise and accurate) for
measuring type II collagen breakdown in clinical settings.
Methods: Quantitation of TIINE-containing 45-mer peptides with
5-hydroxyproline (HyP) was performed by two-dimensional LC-MS/MS,
utilizing an HP1100 high-performance liquid chromatography (HPLC)
system, a CTC Analytics HTS PAL autosampler, switching valve, and
interfaced to an API 4000 triple quadrupole mass spectrometer. A 45-
mer peptide containing 5-Hyp that was deuterated (d5) at the C-terminal
glutamine residue was used as an internal standard. The standard curve
of the 45-mer TIINE peptide was prepared in aqueous solution with
protein present (10 mg/mL of BSA), whereas quality control samples
were made in urine matrix. Methods used for validation were based on
utilizing the authentic peptide spiked into urine samples and evaluated
for sensitivity, selectivity, linearity, accuracy and precision as well as
carry-over, long and short-term stability. Urine samples from the second
morning void were collected without preservatives, aliquoted for separate
